







an Open Access Journal by MDPI

Evolving Landscape of DNA Repair in Cancer Therapy

Guest Editor:

Dr. Yi Chieh Lim

Brain Tumor Biology, Danish Cancer Research Center (DCRC), 2100 Copenhagen, Denmark

Deadline for manuscript submissions:

closed (31 December 2023)

Message from the Guest Editor

Cancer is fundamentally a disease of the genome that is reliant on a compromised DNA damage response (DDR) network to promote oncogenic transformation. Despite the need to undergo mutagenic changes, tumor cells are dependent on a repertoire of DNA repair mechanisms to maintain genome integrity and mediate resistance against genotoxic drugs. With the availability of high-throughput omics data, precision medicine can gain better insights into individual tumor profiles. By detecting vulnerabilities in the different DNA repair pathways, specific targeting can be implemented to eradicate tumor growth.

For this Special Issue, we are interested in featuring original research and review articles that focus on mammalian genome instability pathways and/or the links between DNA repair and cancer.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us